Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.

No abstract is available for this paper.

• Publication year

  1991

• Venue

  British medical journal

• Publication date

  1991-10-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/bmj.303.6807.884PMID 1834291PMCID PMC1671193
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer

  2004cited by this paper
• Randomised trial comparing prednimustine with combination chemotherapy in advanced ovarian carcinoma

  2004cited by this paper
• cis-platinum, adriamycin, and hexamethylmelamine versus cyclophosphamide in advanced ovarian carcinoma

  2004cited by this paper
• Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma.

  1991cited by this paper
• Critical review of the quality and development of randomized clinical trials (RCTs) and their influence on the treatment of advanced epithelial ovarian cancer.

  1990cited by this paper
• Randomized comparison of cyclophosphamide, doxorubicin and cisplatin (CAP) versus cyclophosphamide and doxorubicin (CA) for the treatment of advanced ovarian cancer (ADOVCA). A EORTC Gynecological Cancer Cooperative Group Study.

  1990cited by this paper
• An overview in the treatment of advanced ovarian cancer. MRC Gynaecological Cancer Working Party.

  1990cited by this paper
• Intravenous treosulfan versus intravenous treosulfan plus cisplatinum in advanced ovarian carcinoma

  1990cited by this paper
• Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens.

  1989cited by this paper
• [Prevalence of hepatitis B infection in institutions for the mentally retarded. Epidemiologic characteristics in the province of Vizcaya].

  1989cited by this paper
• Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.

  1989cited by this paper
• A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group.

  1989cited by this paper
• Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

  1989cited by this paper
• Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin.

  1989cited by this paper
• Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer.

  1988cited by this paper
• Cisplatin (P) versus Cyclophosphamide, Adriamycin and Cisplatin (CAP) for Stage III-IV Epithelial Ovarian Carcinoma: A Prospective Randomized Trial

  1988cited by this paper
• Estimates of the worldwide frequency of sixteen major cancers in 1980

  1988cited by this paper
• [Phase III study of carboplatin in ovarian cancer].

  1988cited by this paper
• Carboplatin in combination therapy for ovarian cancer.

  1988cited by this paper
• Randomized trial of the addition of cis‐platin (DDP) and/or BCG to cyclophosphamide (CTX) chemotherapy for ovarian carcinoma

  1987cited by this paper
• Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Gruppo Interegionale Cooperativo Oncologico Ginecologia.

  1987cited by this paper
• A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma.

  1987cited by this paper
• [Controlled prospective study of chemotherapy in advanced ovarian cancer--cyclophosphamide monochemotherapy versus polychemotherapy with adriamycin, cyclophosphamide, 5-fluorouracil and methotrexate].

  1987cited by this paper
• RANDOMISED COMPARISON OF CISPLATIN WITH CYCLOPHOSPHAMIDE/CISPLATIN AND WITH CYCLOPHOSPHAMIDE/DOXORUBICIN/ CISPLATIN IN ADVANCED OVARIAN CANCER

  1987cited by this paper
• Melphalan With and Without Doxorubicin in Advanced Ovarian Cancer

  1987cited by this paper
• A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma.

  1986cited by this paper
• A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study

  1986cited by this paper
• Chemotherapy of advanced ovarian adenocarcinoma: a randomized comparison of combination versus sequential therapy using chlorambucil and cisplatin.

  1986cited by this paper
• Publication bias: the case for an international registry of clinical trials.

  1986cited by this paper
• A randomized study of single agent vs combination chemotherapy in FIGO stages IIB, III and IV ovarian adenocarcinoma.

  1985cited by this paper
• Long-term survival rates with various chemotherapeutic regimens in stages III and IV ovarian adenocarcinoma. The influence of optimum pretreatment surgical resection.

  1985cited by this paper
• Single agent vs. combination chemotherapy for ovarian cancer.

  1985cited by this paper
• Long-term survival rates with various chemotherapeutic regimens in Stages III and IV ovarian adenocarcinoma

  1985cited by this paper
• Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial.

  1985cited by this paper
• A prospective, randomized, national trial for treatment of ovarian cancer: the role of chemotherapy and external irradiation.

  1984cited by this paper
• Comparison of melphalan with cyclophosphamide, methotrexate, and 5‐fluorouracil in patients with ovarian cancer

  1984cited by this paper
• Long-term survival after chemotherapy for advanced epithelial ovarian carcinoma.

  1984cited by this paper
• A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma

  1983cited by this paper
• Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO Stages III and IV) as measured by surgical end-staging (second-look operation).

  1983cited by this paper
• A controlled clinical trial in advanced ovarian cancer.

  1982cited by this paper
• Advanced ovarian cancer: a prospective randomised trial of chlorambucil versus combined cyclophosphamide and cis-diamminedichloroplatinum.

  1982cited by this paper
• Cyclophosphamide plus cis-Platinum in Combination: Treatment Program for Stage III or IV Ovarian Carcinoma

  1982cited by this paper
• Chemotherapy of advanced ovarian carcinoma: Initial experience using a platinum‐based combination

  1982cited by this paper
• Advanced ovarian carcinoma: A prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa‐CAF)

  1981cited by this paper
• MEDICAL RESEARCH COUNCIL STUDY ON CHEMOTHERAPY IN ADVANCED OVARIAN CANCER

  1981cited by this paper
• Medical Research Council study on chemotherapy in advanced ovarian cancer. Medical Research Council's Working Party on ovarian cancer.

  1981cited by this paper
• [Chemo-(hormonal)-therapy of advanced ovarian neoplasms in FIGO stages III and IV. Prospective SAKK-study 20/71].

  1980cited by this paper
• Treatment of women with disseminated or recurrent advanced ovarian cancer with melphalan alone in combination with 5‐fluorouracil and dactinomycin or with the combination of cytoxan, 5‐fluorouracil and dactinomycin

  1980cited by this paper
• Combination v. sequential therapy with melphalan, 5-fluorouracil and methotrexate for advanced ovarian cancer.

  1980cited by this paper
• Advanced ovarian carcinoma: a pilot study of cis-dichlorodiammineplatinum(II) in combination with adriamycin and cyclophosphamide in previously untreated patients and as a single agent in previously treated patients.

  1979cited by this paper
• Different chemotherapeutic sensitivities and host factors affecting prognosis in advanced ovarian carcinoma versus minimal residual disease.

  1979cited by this paper
• Controlled prospective trial of combination chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil for the treatment of advanced ovarian cancer: a preliminary report.

  1979cited by this paper
• Adriamycin therapy for advanced ovarian carcinoma recurrent after chemotherapy.

  1978cited by this paper
• Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.

  1978cited by this paper
• Adriamycin versus adriamycin plus melphalan in advanced ovarian carcinoma.

  1977cited by this paper
• Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary.

  1976cited by this paper

• Germline-Somatic Interactions in BRCA-Associated Cancers: Unique Molecular Profiles and Clinical Outcomes Linking ATM to TP53 Synthetic Essentiality.

  2025cites this paper
• Statistical primer: individual patient data meta-analysis and meta-analytic approaches in case of non-proportional hazards.

  2024cites this paper
• Comparison of the Efficacy of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel in Improving Survival and Quality of Life in the Advanced Ovarian Cancer Patient Population: A Systematic Review and Meta-Analysis of Randomized Control Trials

  2023cites this paper
• Reporting quality and risk of bias of Cochrane individual participant data meta‐analyses: A cross‐sectional study

  2023cites this paper
• Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation.

  2022cites this paper
• Comparison of aggregate and individual participant data approaches to meta-analysis of randomised trials: An observational study

  2020cites this paper
• Individual Participant Data Meta-Analysis

  2020cites this paper
• Let-7e Suppresses DNA Damage Repair and Sensitizes Ovarian Cancer to Cisplatin through Targeting PARP1

  2019cites this paper
• Clinical Presentation and Risk Assessment of Ovarian Tumors in Baghdadian Women

  2019cites this paper
• Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study.

  2018cites this paper
• Clinical Trials in Ovarian Cancer

  2017cites this paper
• Overcoming the Road Blocks: Advancement of Block Copolymer Micelles for Cancer Therapy in the Clinic.

  2017cites this paper
• Xiaoaiping combined with cisplatin can inhibit proliferation and invasion and induce cell cycle arrest and apoptosis in human ovarian cancer cell lines.

  2017cites this paper
• How individual participant data meta-analyses have influenced trial design, conduct, and analysis

  2015cites this paper
• Survival Benefit of Neoadjuvant Chemotherapy for Resectable Cancer of the Gastric and Gastroesophageal Junction: A Meta-Analysis

  2015cites this paper
• Limited efficacy of platinum-based adjuvant treatment on the outcome of borderline ovarian tumors.

  2015cites this paper
• Comparative Effectiveness of Chemotherapy Regimens in Prolonging Survival for Two Large Population‐Based Cohorts of Elderly Adults with Breast and Colon Cancer in 1992–2009

  2015cites this paper
• Individual Participant Data (IPD) Meta-analyses of Randomised Controlled Trials: Guidance on Their Use

  2015cites this paper
• A meta-analysis on the impact of platinum-based adjuvant treatment on the outcome of borderline ovarian tumors with invasive implants.

  2015cites this paper
• Development of Cytotoxic Natural Killer Cells for Ovarian Cancer Treatment

  2015cites this paper
• Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.

  2015cites this paper
• Individual patient data meta-analysis is needed in Chinese medical research

  2014cites this paper
• Clinicopathologic features of brain metastases from gynecologic malignancies: a retrospective study of 139 cases (KCOG-G1001s trial).

  2013cites this paper
• Comparative effectiveness of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer

  2013cites this paper
• Systemische Induktionschemotherapie bei fortgeschrittenem epithelialem Ovarialkarzinom

  2013cites this paper
• Nanocarriers for delivery of platinum anticancer drugs.

  2013cites this paper
• Pharmaceutical Management of Ovarian Cancer

  2012cites this paper
• Intraperitoneal, Continuous Carboplatin Delivery for the Treatment of Ovarian Cancer

  2012cites this paper
• New Developments and Approaches in the Platinum Arena

  2012cites this paper
• Systemic Induction Chemotherapy for Advanced Stage Epithelial Ovarian Cancer

  2011cites this paper
• Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial.

  2011cites this paper
• Trends in treatment of advanced epithelial ovarian cancer in the Medicare population.

  2011cites this paper
• Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics

  2011cites this paper
• Ovarialkarzinom: alte Probleme und neue Lösungsansätze

  2011cites this paper
• Review: Practical considerations in ovarian cancer chemotherapy

  2010cites this paper
• Tamoxifen for relapse of ovarian cancer.

  2010cites this paper
• Scope of nanotechnology in ovarian cancer therapeutics

  2010cites this paper
• Achievements and unmet needs in the management of advanced ovarian cancer.

  2010cites this paper
• Role of meta-analyses and of large randomized trials in the study of cancer treatments.

  2009cites this paper
• Enhancing the efficacy of cisplatin in ovarian cancer treatment – could arsenic have a role

  2009cites this paper
• Management of women with newly diagnosed ovarian cancer.

  2009cites this paper
• Clinical Outcome and Prognostic Factors in Borderline Ovarian Tumors and Invasive Ovarian Carcinomas in Western Sweden

  2008cites this paper
• The selection and use of essential medicines.

  2008cites this paper
• Reviews in Medicine Oncology

  2008cites this paper
• Intraperitoneal Chemotherapy of Ovarian Cancer

  2007cites this paper
• Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group

  2007cites this paper
• The dangers of “cross‐trial” and “cross‐retrospective experience” comparisons

  2007cites this paper
• Current practice and new developments in ovarian cancer chemotherapy

  2007cites this paper
• Perfil imunohistoquímico das proteínas da família BCL-2 e evolução clínica do câncer de ovário : uma análise de pacientes do Hospital de Clínicas de Porto Alegre/Brasil (1996 a 2004)

  2007cites this paper
• The dilemma of carboplatin-associated hypersensitivity reactions in ovarian cancer management.

  2007cites this paper
• Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer.

  2007cites this paper
• A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: a study by the Scottish Gynaecological Cancer Trials Group (SGCTG).

  2006cites this paper
• Optimizing gemcitabine regimens in ovarian cancer.

  2006cites this paper
• A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study.

  2006cites this paper
• Key clinical trials in gynaecological oncology.

  2006cites this paper
• Multimodal approach to ovarian cancer.

  2006cites this paper
• Post-operative sequential high-dose chemotherapy with haematopoietic stem cell support as front-line treatment in advanced ovarian cancer: a phase II multicentre study

  2006cites this paper
• Diagnosis and Management of Epithelial Ovarian Cancer

  2006cites this paper
• Facteurs pronostiques et chimiothérapie de première ligne des adénocarcinomes ovariens

  2006cites this paper
• First‐line gemcitabine and carboplatin in advanced ovarian carcinoma: a phase II study

  2006cites this paper
• Long-term survival in a randomized study of nonplatinum therapy versus platinum in advanced epithelial ovarian cancer

  2006cites this paper
• Management of ovarian cancer. An impressive history of improvement in survival and quality of life.

  2006cites this paper
• Investigation of ototoxic effects of Taxol on a mice model.

  2006cites this paper
• Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments.

  2006cites this paper
• Carboplatin and cisplatin: are they equivalent in efficacy in “optimal residual” advanced ovarian cancer?

  2005cites this paper
• Role of chemotherapy in the management of epithelial ovarian cancer

  2005cites this paper
• The use of the Calvert formula to determine the optimal carboplatin dosage

  2005cites this paper
• Chemotherapy in Advanced Non-Small Cell Lung Cancer

  2005cites this paper
• Advances in the understanding and treatment of ovarian cancer

  2005cites this paper
• Chemotherapy in advanced non-small cell lung cancer.

  2005cites this paper
• The role of platinum dose intensity in the management of ovarian cancer

  2005cites this paper
• A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma* A Ovary

  2005cites this paper
• Neoadjuvant chemotherapy for invasive bladder cancer.

  2005cites this paper
• Current management of ovarian carcinoma

  2005cites this paper
• Effective Inhibition of Experimental Human Ovarian Cancers with a Targeted Cytotoxic Bombesin Analogue AN-215

  2005cites this paper
• Cáncer de ovario

  2005cites this paper
• The Gynecologic Cancer Intergroup (GCIG): history and current status.

  2005cites this paper
• Phase II study of pirarubicin combined with cisplatin in recurrent ovarian cancer

  2005cites this paper
• Place de la chimiothérapie de première ligne dans le cancer de l’ovaire

  2005cites this paper
• Ovarian cancer management. Practice guidelines for nuclear physicians.

  2004cites this paper
• The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.

  2004cites this paper
• Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer: correlation with clinical outcome.

  2004cites this paper
• Adjuvant Treatment for Early-Stage Epithelial Ovarian Cancer

  2004cites this paper
• Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study.

  2004cites this paper
• Androgens and ovarian cancers.

  2004cites this paper
• Remaining controversies in the upfront management of advanced ovarian cancer

  2004cites this paper
• Mutational spectrum of p53 mutations in primary breast and ovarian tumors.

  2004cites this paper
• Patterns and outcomes of chemotherapy for elderly patients with stage II ovarian cancer: a population-based study.

  2004cites this paper
• The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies.

  2004cites this paper
• Évolution des pratiques thérapeutiques et survie du cancer de l'ovaire dans le département de la Côte d'Or de 1982 à 1996 : données du Registre des cancers gynécologiques de Côte d'Or

  2004cites this paper
• Chirurgie de fermeture et chimiothérapie intra-péritonéale dans les cancers de l'ovaire de stade avancé ou en récidive

  2004cites this paper
• Preclinical pharmacology of 1069C85, a novel tubulin binder

  2004cites this paper
• Investigating patient exclusion bias in meta-analysis.

  2004cites this paper
• Brain metastases from epithelial ovarian cancer

  2004cites this paper
• Peripheral Neuropathy Due to Biweekly Paclitaxel, Epirubicin and Cisplatin in Patients with Advanced Ovarian Cancer

  2004cites this paper
• Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and-resistant human ovarian carcinoma cell lines

  2004cites this paper
• Metals and metal compounds in cancer treatment.

  2004cites this paper
• [Evolution of therapeutic practices and survival of ovarian cancer in Bourgandi between 1982-1996: a registry-based study].

  2004cites this paper
• Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer.

  2004cites this paper
• Levels of absolute survival benefit for systemic therapies of advanced cancer. a call for standards.

  2003cites this paper